MSS only

我们是谁

  • 12 月 8, 2022
    Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status
  • 12 月 8, 2022
    FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
  • 12 月 8, 2022
    Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
  • 12 月 8, 2022
    Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer
  • 12 月 1, 2022
    Phase 2 Study of DKN-01 in Colorectal Cancer
  • 11 月 15, 2022
    Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303)
  • 7 月 26, 2022
    一项针对转移性结直肠癌晚期患者的 Nivolumab-relatlimab 固定剂量联合疗法对比瑞戈非尼或 TAS-102 的研究
  • 4 月 5, 2022
    NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
  • 4 月 5, 2022
    Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors
  • 4 月 5, 2022
    CR6086 联合 Balstilimab 治疗 pMMR-MSS 转移性结直肠癌患者的 Ib/IIa 期研究